Feasibility and Effectiveness of Norepinephrine Outside the Intensive Care Setting for Treatment of Hepatorenal Syndrome
Allison Kwong, W. Ray Kim, Paul Y. Kwo, Uerica Wang, Xingxing Cheng – 9 April 2021 – Vasoconstrictors are the treatment of choice for hepatorenal syndrome (HRS). We evaluate the real‐life effectiveness of a sequential vasoconstrictor regimen of midodrine–octreotide followed by norepinephrine in a nonintensive care unit (non‐ICU) setting in the United States, where terlipressin is not available. The diagnosis of HRS and definitions of response to therapy were based on 2015 guidelines from the International Club of Ascites.